The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Drug resistance and combating drug resistance in cancer
Open accessAbstract
Cancer is the second leading cause of death in the US. Current major treatments for cancer management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy, endocrine therapy and immunotherapy. Despite the endeavors and achievements made in treating cancers during the past decades, resistance to classical chemotherapeutic agents and/or novel targeted drugs continues to be a major problem in cancer therapies. Drug resistance, either existing before treatment (intrinsic) or generated after therapy (acquired), is responsible for most relapses of cancer, one of the major causes of death of the disease. Heterogeneity among patients and tumors, and the versatility of cancer to circumvent therapies make drug resistance more challenging to deal with. Better understanding the mechanisms of drug resistance is required to provide guidance to future cancer treatment and achieve better outcomes. In this review, intrinsic and acquired resistance will be discussed. In addition, new discoveries in mechanisms of drug resistance will be reviewed. Particularly, we will highlight roles of ATP in drug resistance by discussing recent findings of exceptionally high levels of intratumoral extracellular ATP as well as intracellular ATP internalized from extracellular environment. The complexity of drug resistance development suggests that combinational and personalized therapies, which should take ATP into consideration, might provide better strategies and improved efficacy for fighting drug resistance in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bhuvanalakshmi, G., Arfuso, F., Millward, M., Dharmarajan, A., & Warrier, S. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127517 · Cited by 72
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 2×
“Ample evidence has shown that subpopulations of cancer cells with various genetic makeups co-exist in primary tumors like ovarian cancer([100]), renal cell carcinoma([101]), breast cancer([102]), and chronic lymphocytic leukemia([103]).”
BackgroundRegulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“Tumors are not bags of homogeneous cancer cells, but contain various types of cells and extracellular matrix (ECM) that work together to contribute to all aspects of the hallmarks of cancer([106,107]).”
BackgroundOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1×
“Cellular senescence refers to irreversible arrest of cell proliferation, largely leading to activation of tumor suppressive pathways mediated by p53 and/or p16INK4a[83].”
BackgroundHermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Cancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237
Evolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
Sensors and regulators of intracellular pH
Casey, J. R., Grinstein, S., & Orlowski, J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2820 · Cited by 2,218
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Vander Jagt, D. L., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,516
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Cooperation and Competition in the Evolution of ATP-Producing Pathways
Pfeiffer, T., Schuster, S., & Bonhoeffer, S. (2001) · Science · doi:10.1126/science.1058079 · Cited by 1,354
Cellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338
CD39 and CD73 in immunity and inflammation
Antonioli, L., Pacher, P., Vizi, E. S., & Haskó, G. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.03.005 · Cited by 1,263
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
Senescence-associated reprogramming promotes cancer stemness
Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., Dörr, J. R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I. A., et al. (2018) · Nature · doi:10.1038/nature25167 · Cited by 1,131
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Hay, N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,115
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
Self-citationTargeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
Human ATP-binding cassette (ABC) transporter family
Vasiliou, V., Vasiliou, K., & Nebert, D. W. (2008) · Human Genomics · doi:10.1186/1479-7364-3-3-281 · Cited by 780
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Wu, Q., Yang, Z., Nie, Y., Shi, Y., & Fan, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.013 · Cited by 776
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 723
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Kurrey, N. K., Jalgaonkar, S. P., Joglekar, A. V., Ghanate, A. D., Chaskar, P. D., Doiphode, R. Y., & Bapat, S. A. (2009) · Stem Cells · doi:10.1002/stem.154 · Cited by 655
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Chemotherapy resistance of glioblastoma stem cells
Eramo, A., Ricci-Vitiani, L., Zeuner, A., Pallini, R., Lotti, F., Sette, G., Pilozzi, E., Larocca, L. M., Peschle, C., & De Maria, R. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401872 · Cited by 623
Müller, M., Meijer, C., Zaman, G. J., Borst, P., Scheper, R. J., Mulder, N. H., de Vries, E. G., & Jansen, P. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.13033 · Cited by 617
Structure and mechanism of ABC transporters
Wilkens, S. (2015) · F1000Prime Reports · doi:10.12703/p7-14 · Cited by 591
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor
Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., Chmielowski, B., Staddon, A. P., Cohn, A. L., Shapiro, G. I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411366 · Cited by 582
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 566
Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555
Self-citationRecurrence after surgery in patients with NSCLC.
Uramoto, H., & Tanaka, F. (2014) · PubMed · doi:10.3978/j.issn.2218-6751.2013.12.05 · Cited by 540
The chemistry, physiology and pathology of pH in cancer
Swietach, P., Vaughan-Jones, R. D., Harris, A. L., & Hulikova, A. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0099 · Cited by 539
Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S. V., Brannigan, B. W., Mohapatra, G., Settleman, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1671 · Cited by 531
Inferring tumor progression from genomic heterogeneity
Navin, N., Krasnitz, A., Rodgers, L., Cook, K., Meth, J., Kendall, J., Riggs, M., Eberling, Y., Troge, J., Grubor, V., et al. (2010) · Genome Research · doi:10.1101/gr.099622.109 · Cited by 524
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471
Piccini, A., Carta, S., Tassi, S., Lasiglié, D., Fossati, G., & Rubartelli, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709684105 · Cited by 463
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
Recent Advances in Cancer Therapy: An Overview
Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Vinals, F., & Capella, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941847 · Cited by 446
Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R
Wilhelm, K., Ganesan, J., Müller, T., Dürr, C., Grimm, M., Beilhack, A., Krempl, C. D., Sorichter, S., Gerlach, U. V., Jüttner, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2242 · Cited by 435
Roberson, R. S., Kussick, S. J., Vallieres, E., Chen, S.-Y. J., & Wu, D. Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1270 · Cited by 428
23 Genetic instability induced by the tumor microenvironment
Glazer, P. M., Reynolds, T. Y., & Rockwell, S. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)80581-0 · Cited by 427
Bashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L. M., Roth, A., Rosner, J., Shumansky, K., Kalloger, S., Senz, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4230 · Cited by 421
Chen, W.-X., Liu, X.-M., Lv, M.-M., Chen, L., Zhao, J.-H., Zhong, S.-L., Ji, M.-H., Hu, Q., Luo, Z., Wu, J.-Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095240 · Cited by 420
Tumour heterogeneity and the evolution of polyclonal drug resistance
Burrell, R. A., & Swanton, C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.005 · Cited by 417
Saxena, M., Stephens, M. A., Pathak, H., & Rangarajan, A. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.61 · Cited by 408
Haslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., Weberpals, J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402
Molecular mechanisms for tumour resistance to chemotherapy
Pan, S., Li, Z., He, Z., Qiu, J., & Zhou, S. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12581 · Cited by 401
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance
Siebzehnrubl, F. A., Silver, D. J., Tugertimur, B., Deleyrolle, L. P., Siebzehnrubl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302827 · Cited by 381
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1674 · Cited by 374
Fan, Y., Shen, B., Tan, M., Mu, X., Qin, Y., Zhang, F., & Liu, Y. (2014) · The FEBS Journal · doi:10.1111/febs.12737 · Cited by 370
Transport of glutathione and glutathione conjugates by MRP1
Cole, S. P. C., & Deeley, R. G. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.06.008 · Cited by 369
Metabolic positron emission tomography imaging in cancer detection and therapy response
Zhu, A., Lee, D., & Shim, H. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.11.012 · Cited by 368 · cited 1×
“For example, it is well known from PET-scans that aggressive tumors with poor prognosis are almost always glucose/energy metabolism active tumors([203,204]).”
BackgroundVaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Cole, S. P. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.609248 · Cited by 361
Challagundla, K. B., Wise, P. M., Neviani, P., Chava, H., Murtadha, M., Xu, T., Kennedy, R., Ivan, C., Zhang, X., Vannini, I., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv135 · Cited by 359
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP
Ko, Y. H., Smith, B. L., Wang, Y., Pomper, M. G., Rini, D. A., Torbenson, M. S., Hullihen, J., & Pedersen, P. L. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.047 · Cited by 352
Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345
Structure and mechanism of ABC transporters
Schmitt, L. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00399-8 · Cited by 331
Purinergic signalling and cancer
Burnstock, G., & Di Virgilio, F. (2013) · Purinergic Signalling · doi:10.1007/s11302-013-9372-5 · Cited by 316
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells
Viale, A., De Franco, F., Orleth, A., Cambiaghi, V., Giuliani, V., Bossi, D., Ronchini, C., Ronzoni, S., Muradore, I., Monestiroli, S., et al. (2009) · Nature · doi:10.1038/nature07618 · Cited by 305
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Wang, S., Cang, S., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0268-z · Cited by 302
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Wang, S., Song, Y., & Liu, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.008 · Cited by 293
Drug rechallenge and treatment beyond progression—implications for drug resistance
Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.158 · Cited by 286
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
Wu, Y., Ginther, C., Kim, J., Mosher, N., Chung, S., Slamon, D., & Vadgama, J. V. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0155-t · Cited by 268
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Drug resistance: Still a daunting challenge to the successful treatment of AML
Shaffer, B. C., Gillet, J.-P., Patel, C., Baer, M. R., Bates, S. E., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.001 · Cited by 259
Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia
Quintás-Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer Control · doi:10.1177/107327480901600204 · Cited by 238
De Angelis, P. M., Svendsrud, D. H., Kravik, K. L., & Stokke, T. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-20 · Cited by 233
The Warburg effect: Evolving interpretations of an established concept
Chen, X., Qian, Y., & Wu, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.027 · Cited by 229
Self-citationRole of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer
Munoz, M., Henderson, M., Haber, M., & Norris, M. (2007) · IUBMB Life · doi:10.1080/15216540701736285 · Cited by 226
Borst, P. (2012) · Open Biology · doi:10.1098/rsob.120066 · Cited by 212
Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance
Stacy, A. E., Jansson, P. J., & Richardson, D. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.088609 · Cited by 210
Long non-coding RNAs in anti-cancer drug resistance
Chen, Q.-N., Wei, C.-C., Wang, Z.-X., & Sun, M. (2017) · Oncotarget · doi:10.18632/oncotarget.12461 · Cited by 209
Ko, A., Kanehisa, A., Martins, I., Senovilla, L., Chargari, C., Dugue, D., Mariño, G., Kepp, O., Michaud, M., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.124 · Cited by 205
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Malek, E., Jagannathan, S., & Driscoll, J. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2469 · Cited by 195
Wang, S., Tsui, S. T., Liu, C., Song, Y., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0290-1 · Cited by 194
Regulation of multidrug resistance by microRNAs in anti-cancer therapy
An, X., Sarmiento, C., Tan, T., & Zhu, H. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.002 · Cited by 194
Sayan, A. E., Griffiths, T. R., Pal, R., Browne, G. J., Ruddick, A., Yagci, T., Edwards, R., Mayer, N. J., Qazi, H., Goyal, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902042106 · Cited by 192
Extracellular ATP in T-lymphocyte activation: possible role in effector functions.
Filippini, A., Taffs, R. E., & Sitkovsky, M. V. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8267 · Cited by 190
Kitamura, K., Seike, M., Okano, T., Matsuda, K., Miyanaga, A., Mizutani, H., Noro, R., Minegishi, Y., Kubota, K., & Gemma, A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0448 · Cited by 187
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
Yang, H., Ma, Y., Chen, G., Zhou, H., Yamazaki, T., Klein, C., Pietrocola, F., Vacchelli, E., Souquere, S., Sauvat, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149673 · Cited by 185
Endocrine Therapy of Breast Cancer
Lumachi, F., Luisetto, G., M.M. Basso, S., Basso, U., Brunello, A., & Camozzi, V. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794480177 · Cited by 176
Bindra, R. S., & Glazer, P. M. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.03.013 · Cited by 168
Likhite, V. S., Stossi, F., Kim, K., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0068 · Cited by 167
CD73 and adenosine generation in the creation of regulatory microenvironments
Regateiro, F. S., Cobbold, S. P., & Waldmann, H. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04623.x · Cited by 166
miR-200c Inhibits Melanoma Progression and Drug Resistance through Down-Regulation of Bmi-1
Liu, S., Tetzlaff, M. T., Cui, R., & Xu, X. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.009 · Cited by 165
Zhang, Z., Liu, S., Shi, R., & Zhao, G. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.07.004 · Cited by 162
Lee, S. H., Oh, S.-Y., Do, S. I., Lee, H. J., Kang, H. J., Rho, Y. S., Bae, W. J., & Lim, Y. C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.528 · Cited by 161
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Ma, C., Wei, S., & Song, Y. J. (2011) · PubMed · doi:10.3978/j.issn.2072-1439.2010.12.02 · Cited by 158
Intrinsic and Acquired Drug Resistance in Malignant Tumors
Lippert, T. H., Ruoff, H. J., & Volm, M. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296504 · Cited by 154
Liao, B.-C., Lin, C., & Yang, J. C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000164 · Cited by 150
Qian, Y., Wang, X., Liu, Y., Li, Y., Colvin, R. A., Tong, L., Wu, S., & Chen, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.008 · Cited by 149
Self-citationCancer Drug Resistance: A Brief Overview from a Genetic Viewpoint
Rueff, J., & Rodrigues, A. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_1 · Cited by 144
P2X7: a growth-promoting receptor—implications for cancer
Virgilio, F. D., Ferrari, D., & Adinolfi, E. (2009) · Purinergic Signalling · doi:10.1007/s11302-009-9145-3 · Cited by 143
Enlightening the impact of immunogenic cell death in photodynamic cancer therapy
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.2 · Cited by 142
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
McCullough, A. E. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.10.022 · Cited by 142
Cellular senescence and cancer chemotherapy resistance
Gordon, R. R., & Nelson, P. S. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.002 · Cited by 141
Kokubo, Y., Gemma, A., Noro, R., Seike, M., Kataoka, K., Matsuda, K., Okano, T., Minegishi, Y., Yoshimura, A., Shibuya, M., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602559 · Cited by 137
Lal, S., Wong, Z. W., Sandanaraj, E., Xiang, X., Ang, P., Lee, E. J. D., & Chowbay, B. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00744.x · Cited by 137
Down-Regulation of miR-27a Might Reverse Multidrug Resistance of Esophageal Squamous Cell Carcinoma
Zhang, H., Li, M., Han, Y., Hong, L., Gong, T., Sun, L., & Zheng, X. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1051-6 · Cited by 136
Self-citationDetecting adenosine triphosphate in the pericellular space
Falzoni, S., Donvito, G., & Di Virgilio, F. (2013) · Interface Focus · doi:10.1098/rsfs.2012.0101 · Cited by 136
Gridelli, C., de Marinis, F., Maïo, M. D., Cortinovis, D. L., Cappuzzo, F., & Mok, T. S. K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.008 · Cited by 133
Huang, D., Duan, H., Huang, H., Tong, X., Han, Y. K., Ru, G., Qu, L., Shou, C., & Zhao, Z. (2016) · Scientific Reports · doi:10.1038/srep20502 · Cited by 133
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Wang, Y., Schmid‐Bindert, G., & Zhou, C. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011427927 · Cited by 125
TGF-β: An emerging player in drug resistance
Brunen, D., Willems, S., Kellner, U., Midgley, R., Simon, I., & Bernards, R. (2013) · Cell Cycle · doi:10.4161/cc.26034 · Cited by 124
Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, M., Papaccio, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3319 · Cited by 122
The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
Hou, Y., Zhu, Q., Li, Z., Peng, Y., Yu, X., Yuan, B., Liu, Y., Liu, Y., Yin, L., Peng, Y., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.53 · Cited by 121
Cho, S., Lü, M., He, X., Ee, P. L. R., Bhat, U. G., Schneider, E., Miele, L., & Beck, W. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019452108 · Cited by 115
Shang-Hsun, T., Chen, T.-M., Hsiao, H.-T., & Chen, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116747 · Cited by 111
Sabisz, M., & Składanowski, A. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9758 · Cited by 110
Schafer, J. M., Liu, H., Bentrem, D. J., Zapf, J. W., & Jordan, V. C. (2000) · PubMed · Cited by 109
Qian, Y., Wang, X., Li, Y., Cao, Y., & Chen, X. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0118 · Cited by 108
Self-citationJabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
Micro RNA s and their relevance to ABC transporters
Haenisch, S., Werk, A. N., & Cascorbi, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12251 · Cited by 101
Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance
Andugulapati, S. B., Udupa, N., Chamallamudi, M. R., Gupta, V., & Rangarajan, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155013 · Cited by 100
Angelis, P. D., Fjell, B., Kravik, K., Haug, T., Tunheim, S. H., Reichelt, W. H., Beigi, M., Clausen, O. P. F., Galteland, E., & Stokke, T. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.5.1279 · Cited by 99
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide
Lagas, J. S., Fan, L., Wagenaar, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1321 · Cited by 97
Li, J., Liu, H., Yu, J., & Yu, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3356 · Cited by 96
In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model
Morrone, F. B., de Oliveira, D. L., Gamermann, P. W., Stella, J., Wofchuk, S., Wink, M. R., Meurer, L., Edelweiss, M. I. A., Lenz, G., & Battastini, A. M. O. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-226 · Cited by 94
Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma
Azzarito, T., Venturi, G., Cesolini, A., & Fais, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.017 · Cited by 91
Sun, L., Ke, J., He, Z., Chen, Z., Huang, Q., Ai, W., Wang, G., Wei, Y., Zou, X., Zhang, S., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19142 · Cited by 91
Sui, H. X., Cai, G.-X., Pan, S.-F., Deng, W.-L., Wang, Y., Chen, Z., Cai, S.-J., Zhu, H.-R., & Li, Q. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0167 · Cited by 89
Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression
Jiang, Z., Sun, Y., Wang, S., & Ruan, J. (2017) · Journal of Cancer · doi:10.7150/jca.19079 · Cited by 87
Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells
Pecqueur, C., Oliver, L., Oizel, K., Lalier-Bretaudeau, L., & Vallette, F. M. (2013) · International Journal of Cell Biology · doi:10.1155/2013/805975 · Cited by 84
Wang, X., Li, Y., Qian, Y., Cao, Y., Shriwas, P., Zhang, H., & Chen, X. (2017) · Oncotarget · doi:10.18632/oncotarget.21231 · Cited by 82
Self-citationZhou, Z., Zhang, L., Xie, B., Wang, X., Yang, X., Ding, N., Zhang, J., Liu, Q., Tan, G., Feng, D., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.008 · Cited by 81
Self-citationGenomics and the mechanism of P-glycoprotein (ABCB1)
Sauna, Z. E., Kim, I., & Ambudkar, S. V. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9115-9 · Cited by 80
ABCC3 as a marker for multidrug resistance in non-small cell lung cancer
Zhao, Y., Lu, H., An, Y., Yang, Y., Meng, Q., Sun, L., Pang, H., Li, C., Dong, X., & Cai, L. (2013) · Scientific Reports · doi:10.1038/srep03120 · Cited by 80
Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
Tang, J., Salama, R., Gadgeel, S. M., Sarkar, F. H., & Ahmad, A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00015 · Cited by 73
Limami, Y., Pinon, A., Leger, D. Y., Pinault, É., Delage, C., Beneytout, J., Simon, A., & Liagre, B. (2012) · Biochimie · doi:10.1016/j.biochi.2012.04.006 · Cited by 73
Peng, X., Tiwari, A. K., Wu, H.-C., & Chen, Z. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10327 · Cited by 73
Twist mediates an aggressive phenotype in human colorectal cancer cells
Deng, J., Zhang, W., Xu, X., Zhang, F., Tao, W., Ye, J., & Ge, W. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3342 · Cited by 71
The network of P-glycoprotein and microRNAs interactions
Lopes-Rodrigues, V., Seca, H., Sousa, D., Sousa, E., Lima, R. T., & Vasconcelos, M. H. (2013) · International Journal of Cancer · doi:10.1002/ijc.28500 · Cited by 69
Zhu, K., Chen, L., Han, X., Wang, J., & Wang, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1633 · Cited by 69
Functional genomics of calcium channels in human melanoma cells
Deli, T., Varga, N., Ádám, A., Kenessey, I., Rásó, E., Puskás, L. G., Tóvári, J., Fodor, J., Fehér, M., Szigeti, G. P., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22621 · Cited by 68
Hu, J., Qiu, M., Jiang, F., Zhang, S., Yang, X., Wang, J., Xu, L., & Yin, R. H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2158-8 · Cited by 66
Uchibori, K., Kasamatsu, A., Sunaga, M., et al. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1300 · Cited by 65
pH Gradient Reversal: An Emerging Hallmark of Cancers
Sharma, M., Astekar, M. S., Soi, S., Manjunatha, B. S., Shetty, D. C., & Radhakrishnan, R. A. (2015) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892810666150708110608 · Cited by 60
ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC
Lazarova, D. L., & Bordonaro, M. (2017) · Journal of Cancer · doi:10.7150/jca.18762 · Cited by 59
Yin, J., & Zhang, J. (2011) · PubMed · doi:10.3969/j.issn.1672-7347.2011.10.002 · Cited by 58
Gillet, J., Calcagno, A. M., Varma, S., Davidson, B., Elstrand, M. B., Ganapathi, R. N., Kamat, A. A., Sood, A. K., Ambudkar, S. V., Seiden, M. V., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0056 · Cited by 57
Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer
Zeller, C., & Brown, R. E. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010375759 · Cited by 56
Damin, D. C., & Lazzaron, A. R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.877 · Cited by 53
O’Connor, D., Sibson, K. R., Caswell, M., Connor, P., Cummins, M., Mitchell, C., Motwani, J., Taj, M., Vora, A. J., Wynn, R. F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08752.x · Cited by 50
Amin, A. D., Rajan, S. S., Liang, W. S., Pongtornpipat, P., Groysman, M. J., Tapia, E. O., Peters, T. L., Cuyugan, L., Adkins, J. R., Rimsza, L. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3437 · Cited by 48
Chen, W., Wang, H., Tang, Y., Liu, C., Li, H., & Li, W. (2010) · 癌症:英文版 · doi:10.5732/cjc.009.10447 · Cited by 48
Contribution of intracellular ATP to cisplatin resistance of tumor cells
Schneider, V., Krieger, M. L., Bendas, G., Jaehde, U., & Kalayda, G. V. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0960-6 · Cited by 44
Ohata, Y., Shimada, S., Akiyama, Y., Mogushi, K., Nakao, K., Matsumura, S., Aihara, A., Mitsunori, Y., Ban, D., Ochiai, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0728 · Cited by 44
Li, W., Liu, C., Tang, Y., Li, H., Zhou, F., & Lv, S. (2011) · PubMed · Cited by 43
Intrinsic Resistance to Chemotherapy in Breast Cancer
Moulder, S. (2010) · Women s Health · doi:10.2217/whe.10.60 · Cited by 42
Inhibitors of glucose transport and glycolysis as novel anticancer therapeutics
Qian, Y. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i2.37 · Cited by 41
Vinette, V., Placet, M., Arguin, G., & Gendron, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136080 · Cited by 32
Mato, E., González, C., Moral, A., Pérez, J. I., Bell, O. L., Lerma, E., & de Leiva, A. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0051 · Cited by 27
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Metadata
- Authors
- Wang, X., Zhang, H., & Chen, X.
- Venue
- Cancer Drug Resistance
- Publisher
- OAE Publishing Inc.
- Published
- 2019
- Volume
- 2
- Pages
- 141-160
- ISSN
- 2578-532X (ISSN-L)
- OpenAlex
- W2938150871
- Cited by
- 1,085
- References
- 194
- FWCI
- 31.01
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.